EGCG Protects against 6-OHDA-Induced Neurotoxicity in a Cell Culture Model

Parkinson's Disease

Volumn 2015, Issue , 2015, Pages

  Chen, Dan ^a   Kanthasamy, Anumantha G ^a   Reddy, Manju B ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; FERROPORTIN 1; HEPCIDIN; IRON 55; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; OXIDOPAMINE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; IMMUNOCYTOCHEMISTRY; IRON METABOLISM; IRON TRANSPORT; MOUSE; NERVE CELL CULTURE; NEURITE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84953327061     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2015/843906     Document Type: Article

References (48)

1. R. Hansch and R. R. Mendel, "Physiological functions of mineral micronutrients (Cu, Zn, Mn, Fe, Ni, Mo, B, Cl), " Current Opinion in Plant Biology, vol. 12, no. 3, pp. 259-266, 2009.
2. M. C. Linder, "Mobilization of stored iron in mammals: a review, " Nutrients, vol. 5, no. 10, pp. 4022-4050, 2003.
3. M. W. Hentze, M. U. Muckenthaler, and N. C. Andrews, "Balancing acts:molecular control ofmammalian ironmetabolism, " Cell, vol. 117, no. 3, pp. 285-297, 2004.
4. M. B. H. Youdim, D. Ben-Shachar, and P. Riederer, "The possible role of iron in the etiopathology of Parkinsons disease, " Movement Disorders, vol. 8, no. 1, pp. 1-12, 1993.
5. C. M. Cahill, D. K. Lahiri, X. Huang, and J. T. Rogers, "Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases, " Biochimica et Biophysica Acta-General Subjects, vol. 1790, no. 7, pp. 615-628, 2009.
6. K. Jomova, D. Vondrakova, M. Lawson, and M. Valko, "Metals, oxidative stress and neurodegenerative disorders, " Molecular and Cellular Biochemistry, vol. 345, no. 1-2, pp. 91-104, 2010.
7. H. Jiang, N. Song, H. Xu, S. Zhang, J. Wang, and J. Xie, "Upregulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent, " Cell Research, vol. 20, no. 3, pp. 345-356, 2010.
8. S. Zhang, J. Wang, N. Song, J. Xie, and H. Jiang, "Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4- phenylpyridinium (MPP(+))-induced apoptosis in MES23. 5 cells, " Neurobiology of Aging, vol. 30, no. 9, pp. 1466-1476, 2009.
9. J. Salazar, N. Mena, S. Hunot et al., "Divalent metal transporter (DMT1) contributes to neurodegeneration in animal models of Parkinsons disease, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 47, pp. 18578-18583, 2008.
10. I. DeDomenico, E. Lo, B. Yang et al., "Therole of ubiquitination in hepcidin-independent and hepcidin-dependent degradation of ferroportin, " CellMetabolism, vol. 14, no. 5, pp. 635-646, 2011.
11. D. D. Harrison-Findik, "Gender-related variations in iron metabolism and liver diseases, " World Journal of Hepatology, vol. 2, no. 8, pp. 302-310, 2010.
12. G. N. L. Jameson, R. F. Jameson, and W. Linert, "New insights into iron release from ferritin: direct observation of the neurotoxin 6-hydroxydopamine entering ferritin and reaching redox equilibrium with the iron core, " Organic and Biomolecular Chemistry, vol. 2, no. 16, pp. 2346-2351, 2004.
13. K. L. Double, M. Maywald, M. Schmittel, P. Riederer, and M. Gerlach, "In vitro studies of ferritin iron release and neurotoxicity, " Journal of Neurochemistry, vol. 70, no. 6, pp. 2492-2499, 1998.
14. Y. Levites, O. Weinreb, G. Maor, M. B. H. Youdim, and S. Mandel, "Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced dopaminergic neurodegeneration, " Journal of Neurochemistry, vol. 78, no. 5, pp. 1073-1082, 2001.
15. E. Grunblatt, S. Mandel, and M. B. H. Youdim, "Neuroprotective strategies in Parkinsons disease using the models of 6- hydroxydopamine and MPTP, " Annals of the New York Academy of Sciences, vol. 899, pp. 262-273, 2000.
16. H. Jin, A. Kanthasamy, A. Ghosh, Y. Yang, V. Anantharam, and A. G. Kanthasamy, " -synuclein negatively regulates protein kinase C expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity, " The Journal of Neuroscience, vol. 31, no. 6, pp. 2035-2051, 2011.
17. H. Afeseh Ngwa, A. Kanthasamy, V. Anantharam et al., "Vanadium induces dopaminergic neurotoxicity via protein kinase Cdelta dependent oxidative signalingmechanisms: relevance to etiopathogenesis of Parkinsons disease, " Toxicology and Applied Pharmacology, vol. 240, no. 2, pp. 273-285, 2009.
18. C. Latchoumycandane, V. Anantharam, M. Kitazawa, Y. Yang, A. Kanthasamy, and A. G. Kanthasamy, "Protein kinase Cdelta is a key downstreammediator of manganese-induced apoptosis in dopaminergic neuronal cells, " Journal of Pharmacology and Experimental Therapeutics, vol. 313, no. 1, pp. 46-55, 2005.
19. S. Kaul, V. Anantharam, Y. Yang, C. J. Choi, A. Kanthasamy, and A. G. Kanthasamy, "Tyrosine phosphorylation regulates the proteolytic activation of protein kinase C in dopaminergic neuronal cells, " The Journal of Biological Chemistry, vol. 280, no. 31, pp. 28721-28730, 2005.
20. Y. Yang, S. Kaul, D. Zhang, V. Anantharam, and A. G. Kanthasamy, "Suppression of caspase-3-dependent proteolytic activation of protein kinase C by small interfering RNA prevents MPP+-induced dopaminergic degeneration, " Molecular and Cellular Neuroscience, vol. 25, no. 3, pp. 406-421, 2004.
21. N. J. Walker, "Real-time and quantitative PCR: applications to mechanism-based toxicology, " Journal of Biochemical and Molecular Toxicology, vol. 15, no. 3, pp. 121-127, 2001.
22. X. Wang, M. D. Garrick, F. Yang, L. A. Dailey, C. A. Piantadosi, and A. J. Ghio, "TNF, IFN- and endotoxin increase expression of DMT1 in bronchial epithelial cells, " American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 289, no. 1, pp. L24-L33, 2005.
23. S. Guo, E. Bezard, and B. Zhao, "Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway, " Free Radical Biology and Medicine, vol. 39, no. 5, pp. 682-695, 2005.
24. C. Casteels, E. Lauwers, G. Bormans, V. Baekelandt, and K. Van Laere, "Metabolic-dopaminergic mapping of the 6- hydroxydopamine rat model for Parkinsons disease, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 124-134, 2008.
25. H. G. Kim, M. S. Ju, D.-H. Kim et al., "Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinsons disease, " Basic and Clinical Pharmacology and Toxicology, vol. 107, no. 6, pp. 958-964, 2010.
26. G. Walkinshaw and C. M. Waters, "Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis, " Neuroscience, vol. 63, no. 4, pp. 975-987, 1994.
27. J. Rodriguez-Pallares, J. A. Parga, A. M͡noz, P. Rey, M. J. Guerra, and J. L. Labandeira-Garcia, "Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons, " Journal of Neurochemistry, vol. 103, no. 1, pp. 145-156, 2007.
28. A. G. Kanthasamy, V. Anantharam, D. Zhang et al., "A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKC) protects against dopaminergic neuronal degeneration in Parkinsons disease models, " Free Radical Biology and Medicine, vol. 41, no. 10, pp. 1578-1589, 2006.
29. W.-S. Chan, S. S. K. Durairajan, J.-H. Lu et al., "Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture, " Neurochemistry International, vol. 55, no. 6, pp. 414-422, 2009.
30. N. Song, H. Jiang, J. Wang, and J.-X. Xie, "Divalent metal transporter up-regulation is involved in the 6-hydroxydopamineinduced ferrous iron influx, " Journal of Neuroscience Research, vol. 85, no. 14, pp. 3118-3126, 2007.
31. H. P. Monteiro and C. C. Winterbourn, "6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation, " Biochemical Pharmacology, vol. 38, no. 23, pp. 4177-4182, 1989.
32. H. Xu, H. Jiang, J. Wang, and J. Xie, "Rg1 protects ironinduced neurotoxicity through antioxidant and iron regulatory proteins in 6-OHDA-treated MES23. 5 cells, " Journal of Cellular Biochemistry, vol. 111, no. 6, pp. 1537-1545, 2010.
33. L. Xu, W.-F. Chen, and M.-S. Wong, "Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinsons disease through the IGF-I receptor signalling pathway, " British Journal of Pharmacology, vol. 158, no. 3, pp. 738-748, 2009.
34. S.-M. Wang, L.-J. Fu, X.-L. Duan et al., "Role of hepcidin in murine brain iron metabolism, " Cellular and Molecular Life Sciences, vol. 67, no. 1, pp. 123-133, 2010.
35. A. Piperno, R. Mariani, P. Trombini, and D. Girelli, "Hepcidin modulation in human diseases: from research to clinic, " World Journal of Gastroenterology, vol. 15, no. 5, pp. 538-551, 2009.
36. E. Nemeth, A. Roetto, G. Garozzo, T. Ganz, and C. Camaschella, "Hepcidin is decreased in TFR2 hemochromatosis, " Blood, vol. 105, no. 4, pp. 1803-1806, 2005.
37. E. Nemeth and T. Ganz, "Regulation of iron metabolism by hepcidin, " Annual Review of Nutrition, vol. 26, pp. 323-342, 2006.
38. N. Song, J. Wang, H. Jiang, and J. Xie, "Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinsons disease, " Free Radical Biology and Medicine, vol. 48, no. 2, pp. 332-341, 2010.
39. H.-Y. Zhang, N.-D. Wang, N. Song et al., "6-Hydroxydopamine promotes iron traffic in primary cultured astrocytes, " BioMetals, vol. 26, no. 5, pp. 705-714, 2013.
40. C. B. Carroll, M.-L. Zeissler, N. Chadborn et al., "Changes in iron-regulatory gene expression occur in human cell culture models of Parkinsons disease, " Neurochemistry International, vol. 59, no. 1, pp. 73-80, 2011.
41. L. Li, C. Holscher, B.-B. Chen, Z.-F. Zhang, and Y.-Z. Liu, "Hepcidin treatment modulates the expression of divalent metal transporter-1, ceruloplasmin, and ferroportin-1 in the rat cerebral cortex and hippocampus, " Biological Trace Element Research, vol. 143, no. 3, pp. 1581-1593, 2011.
42. J. Yu, Y. Jia, Y. Guo et al., "Epigallocatechin-3-gallate protects motor neurons and regulates glutamate level, " FEBS Letters, vol. 584, no. 13, pp. 2921-2925, 2010.
43. L. Kalfon, M. B. H. Youdim, and S. A. Mandel, "Green tea polyphenol (-)-epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of Bad: implications for neuroprotection, " Journal of Neurochemistry, vol. 100, no. 4, pp. 992-1002, 2007.
44. E. K. Schroeder, N. A. Kelsey, J. Doyle et al., "Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons, " Antioxidants and Redox Signaling, vol. 11, no. 3, pp. 469-480, 2009.
45. Y. Levites, T. Amit, M. B. H. Youdim, and S. Mandel, "Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (?)-epigallocatechin 3-gallate neuroprotective action, "The Journal of Biological Chemistry, vol. 277, no. 34, pp. 30574-30580, 2002.
46. L. Wang, S. Xu, X. Xu, and P. Chan, "(-)-epigallocatechin-3- gallate protects SH-SY5Y cells against 6-OHDA-induced cell death through stat3 activation, " Journal of Alzheimers Disease, vol. 17, no. 2, pp. 295-304, 2009.
47. O. Weinreb, S. Mandel, and M. B. H. Youdim, "cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells, " The FASEB Journal, vol. 17, no. 8, pp. 935-937, 2003.
48. C. Chen, R. Yu, E. D. Owuor, and A.-N. TonyKong, "Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases bymajor green tea polyphenol components during cell survival and death, " Archives of Pharmacal Research, vol. 23, no. 6, pp. 605-612, 2000.